Mauna Kea Technologies: 'Triple Healing' Could Predict Sustained Remission in Ulcerative Colitis
Mauna Kea Technologies highlights a publication from Wednesday in the United European Gastroenterology Journal, which introduces the concept of 'triple healing' as a predictor of sustained remission in ulcerative colitis. This publication is part of a decade of independent research positioning its Cellvizio platform as a diagnostic tool for relapse risk in inflammatory bowel diseases (IBD).
Emerging Clinical Concept of 'Triple Healing'
The prospective study, conducted with 81 patients in clinical and endoscopic remission from ulcerative colitis, incorporates a new clinical definition: 'triple healing', combining histological healing and intestinal permeability integrity at the level of the terminal ileum and colon. Among the 29 patients who reached this stage, none experienced a relapse during the 24-month follow-up period, while the relapse rate reached 33% among patients who did not meet this criterion. This notion represents a potential new therapeutic target marker in the management of ulcerative colitis beyond conventional mucosal healing.
A Scientific Foundation Built Over More Than a Decade
The publication is part of a series of converging prospective results conducted by independent academic centers in Germany, the United Kingdom, Australia, France, and Romania. Since 2012, available studies indicate that confocal imaging of the intestinal barrier detects permeability dysfunctions and microscopic inflammation with greater specificity than conventional endoscopic methods or histology. These studies encompass more than 430 patients from independent cohorts in Mainz, Sydney, Erlangen, and Iași.
Reimbursement: Proven Models of Cellvizio
Mauna Kea Technologies announces its intention to engage in discussions with medical societies and reimbursement bodies to explore a dedicated reimbursement pathway for IBD monitoring. The strategy is based on the model that has worked in diagnosing Barrett's esophagus and pancreatic cysts, areas for which Cellvizio has obtained a dedicated CPT code. The company also plans to explore this advancement with therapeutic developers as a tool for patient stratification and clinical trial goal definition.
